SciNeuro

formerly SciNeuro Pharmaceuticals

Deciphering the Enigma of Brain Disease

Shanghai, China · Founded 2020 · $153.0M raised

Headquarters
Shanghai
Employees
11–50
Founded
2020
Business Model
B2B
Total Funding
$153.0M
Last Round
$53.0M Series BDec 2025
Rounds
2

About

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company transforming scientific discoveries into therapies for central nervous system diseases, with an expert team spanning discovery to clinical development in the US and China. Founded in late 2020 by Dr. Min Li, the company's pipeline addresses neurovascular inflammation, proteinopathy, and immune-driven neurodegeneration, including a blood-brain-barrier shuttle platform for CNS drug delivery. SciNeuro licensed a next-generation anti-amyloid antibody to Novartis for $165 million upfront and up to $1.5 billion in milestones, and separately raised $53 million to advance its pipeline.

Summary

SciNeuro is a Life Sciences company based in Shanghai, China, founded in 2020. It has raised $153.0M in total across 2 rounds, most recently a $53.0M Series B round in Dec 2025. Investors include Lilly Asia Ventures, ARCH Venture Partners and General Atlantic.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BDec 2025
$53.0M

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

SciNeuro on Indexed.vc
<a href="https://indexed.vc/companies/scineuro"><img src="https://indexed.vc/api/badge/company/scineuro" alt="SciNeuro on Indexed.vc" width="260" height="76" /></a>